A public company wanted to assess its opportunity in inlicensing assets in the immune checkpoint blocker field and wanted to position its cell therapeutic portfolio for partnering its technology with a leading player.
MSC identified a number of relevant companies and leading research groups for high-level opportunity assessment. A review was provided of the presented clinical data together with competitive intelligence about each of the candidates and the key opinion leaders. Outcome of the report was used to develop the company’s strategic partnering plan and to create partnering communication material for targeted collaboration efforts at selected conferences. MSC’s delivery was distributed through conference matchmakers and used to attract licensing partners and investments.